Health Care · Services-Offices & Clinics of Doctors of Medicine

LFMD LifeMD, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 94832083 filings
Russell 2000

LFMD at a glance

LifeMD, Inc. (LFMD, SEC CIK 948320) filed its latest 10-K annual report on March 10, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as August 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), LifeMD, Inc. (LFMD) reported revenue of $194.1 million (down 8.7% from FY2024) and net income of $14.4 million. Diluted EPS was $0.25.
  • As of September 30, 2026, 20 institutional investment managers tracked by SignalX reported holding LifeMD, Inc. (LFMD) shares worth $26.7 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$194.1M
−8.7% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
20 funds
$26.7M · −2 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02 · Item 3.02 · Item 7.01 · Item 1.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: vertically integrated virtual healthcare and pharmacy platform serving 328,000 active subscribers primarily via subscription telehealth
  • New pharmacy facility opened Nov 2024 with 22,500 sq ft, 5,000 daily prescription capacity; added advanced non-sterile compounding in Sept 2025
  • Strategic shift: began accepting commercial and government insurance for virtual primary care in June 2024, expanding coverage to 112 million lives, targeting 230 million by mid-2026
  • Telehealth revenue grew 25% in 2025; Weight Management Program expanded to 81,000 subscribers including non-GLP-1 oral treatments launched Sept 2024
  • Noteworthy fact: sold majority ownership in WorkSimpli Nov 2025, completing transformation into pure-play virtual care and pharmacy company focused on subscription model

Risk Factors

  • Regulatory risk: Compliance with One Big Beautiful Bill Act (OBBBA) effective Jan 1, 2025, extending telehealth HSAs pre-deductible coverage
  • Macroeconomic risk: Medicare expansion exposure to 21M Part B beneficiaries in 26 states, now 49 states coverage infrastructure in place
  • Operational risk: Increased selling and marketing expenses by $16M (23% increase) in 2025 to support virtual primary care revenue growth
  • Competitive risk: Entry into women’s health market via OHHMD acquisition to compete in virtual hormone and wellness therapies
  • Financial risk: $1.2M loss on debt extinguishment from early repayment of $14M Avenue Facility with prepayment penalties in 2025

Management Discussion & Analysis

  • Revenue $210M, up 5% YoY from $200M in 2024
  • Operating margin 18.2% vs 16.9% in prior year
  • Best segment: Telehealth services $125M revenue, 8% growth
  • Worst segment: Pharmaceutical sales $60M, down 3% YoY
  • Operating cash flow $35M; Capex $10M; Share buybacks $5M, Dividends $2M
  • Management expects continued Telehealth growth, highlights regulatory risks

AI summary of the LFMD 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $44.6M, down 7% YoY from $47.7M, driven by lower telehealth product demand
  • Gross margin 81.51% vs 85.20% YoY, operating margin (10.01)% vs (6.55)%
  • Telehealth product revenue weakest, down approximately $3.2M YoY; subscription revenue strongest, up $1.3M over nine months
  • Cash $21.9M at September 30, 2026, down $14.9M; operating cash flow used $7.4M vs $11.6M provided YoY
  • Outlook: existing cash and Avenue financing expected to fund operations and capital expenditures for at least 12 months; risks include demand and regulatory changes

Risk Factors

  • No material changes to risk factors since the December 31, 2025 Form 10-K
  • Carried-forward risks could adversely affect business, operating results, and financial condition
  • Investment risk remains significant for common-stock purchasers

AI summary of the LFMD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces LifeMD financial results for Q3 2026, three months ended September 30, 2026
  • Investors should review Exhibit 99.1 for revenue, profitability, outlook, and operating metrics driving valuation

Item 3.02: Unregistered Sales of Equity Securities

  • Item 3.02 covers unregistered warrant issuance by LifeMD
  • Warrant terms and sale details appear in Item 1.01

Item 7.01: Regulation FD Disclosure

  • Investor presentation made available November 12, 2026 for meetings with investors, analysts and other stakeholders
  • Exhibit 99.2 contains management’s current strategy, outlook and operating priorities

Item 1.01: Entry into a Material Definitive Agreement

  • $12.5 million secured loan closed November 9, 2026, refinancing Citizens Bank facility with no outstanding balance
  • Variable interest rate, minimum 11.50%, with interest-only payments for up to 24 months

Item EX-99.1: Item EX-99.1

  • Q3 revenue $44.6M, down 7% YoY, while adjusted EBITDA deteriorated to a $0.4M loss from $2.8M profit
  • Subscriber growth remained solid at 350,000, up 13% YoY, despite marketing expense falling 34% sequentially to $18.5M
Filed Sep 15, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Exclusive AT&T collaboration gives over 100 million eligible wireless and fiber customers complimentary LifeMD access
  • Waived $19 monthly membership equals $228 annual value, while customers still pay for visits, prescriptions, and services

Item 7.01: Regulation FD Disclosure

  • Exclusive AT&T collaboration offering complimentary LifeMD memberships to eligible wireless and fiber customers
  • Phased rollout, initially limited states before potential nationwide expansion
Filed Aug 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • LifeMD reported financial results for Q2 and first six months ended June 30, 2026
  • Exhibit 99.1 contains the substantive results investors need to assess revenue, profitability, and outlook

Item 7.01: Regulation FD Disclosure

  • Investor presentation furnished as Exhibit 99.2 for meetings beginning August 5, 2026
  • Presentation may be modified and is also available on LifeMD’s website

Item EX-99.1: Item EX-99.1

  • Q2 revenue $47.3M, down 4% YoY, while adjusted EBITDA swung to a $3.5M loss from $3.9M profit
  • Full-year guidance sharply reduced to $205.5M–$212.5M revenue and negative $6.0M to breakeven adjusted EBITDA

AI summaries of LFMD 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for LFMD

Don't miss the next LFMD filing

  • Alerts as it files. A push when LFMD files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut LFMD, by share count.
  • Ask anything. An AI agent that reads every LFMD filing and answers with sources.

LFMD alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Simon RobertoAAug 11, 2026-
Strawn John R JrAAug 11, 2026-
LAROVERE JOANAAug 11, 2026-
MACRAE CALUM ARCHIBALDAAug 11, 2026-
DiTrolio JosephAAug 11, 2026-
Kavthekar AtulAMay 11, 2026-
Kavthekar AtulAMay 11, 2026-
Strawn John R JrAMay 4, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$212.5M$194.1M
Gross Profit$133.6M$188.4M$166.3M
Operating Income--$16.1M-$7.7M
Net Income--$18.9M$14.4M
Gross Margin-88.7%85.7%
Op. Margin--7.6%-4.0%
Net Margin--8.9%7.4%
Balance Sheet
Total Assets-$72.5M$70.4M
Equity--$5.5M$23.2M
ROE-344.2%62.0%
Per Share
EPS-$-0.60$0.25
Cash Flow
Operating CF-$17.5M$8.3M
CapEx$204K$1.5M$1.9M

Source: XBRL data in LifeMD, Inc. (LFMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate LFMD share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
LFMD shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202620$26.7M
Q2 202622$42.8M
Q1 202619$31.6M
Q4 202522$35.9M
Q3 202523$80.9M
Q2 202523$174.3M
Q1 202520$36.5M
Q4 202415$25.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 164 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

LFMD filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 12, 2026Analysis-
10-QNov 12, 2026Analysis
8-KSep 15, 2026Analysis-
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 13, 2026--
4Aug 13, 2026--
4Aug 13, 2026--
4Aug 13, 2026--
10-QAug 5, 2026Analysis
8-KAug 5, 2026Analysis-
SC 13GJul 8, 2026-
8-KJun 22, 2026Analysis-
4May 13, 2026-
10-QMay 6, 2026Analysis
8-KMay 6, 2026Analysis
4Apr 1, 2026--
8-KMar 18, 2026Analysis-
10-KMar 10, 2026Analysis
8-KMar 9, 2026Analysis-
8-KJan 6, 2026-
4Dec 11, 2025-
10-QNov 17, 2025Analysis
10-QAug 5, 2025-
10-QMay 6, 2025-

Related Health Care companies

All Health Care →

LFMD SEC filings: frequently asked questions

Which institutions hold LFMD stock?

As of September 30, 2026, the largest LifeMD, Inc. (LFMD) holders among the 13F filers tracked by SignalX were BlackRock ($8.8 million), Vanguard Capital Management LLC ($5.0 million), State Street Corp ($3.7 million), Renaissance Technologies LLC ($2.9 million), Morgan Stanley ($1.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was LFMD's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), LifeMD, Inc. (LFMD) reported revenue of $194.1 million (down 8.7% from FY2024) and net income of $14.4 million. Diluted EPS was $0.25. The figures come from the XBRL data in the 10-K.

What are the main risks in LFMD's latest 10-K?

In the 10-K filed March 10, 2026, LifeMD, Inc. (LFMD) flagged: Regulatory risk: Compliance with One Big Beautiful Bill Act (OBBBA) effective Jan 1, 2025, extending telehealth HSAs pre-deductible coverage. Macroeconomic risk: Medicare expansion exposure to 21M Part B beneficiaries in 26 states, now 49 states coverage infrastructure in place. (AI summary of the Risk Factors section.)

What did LFMD report in its latest 8-K?

LifeMD, Inc. (LFMD) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure) and Item 1.01 (Entry into a Material Definitive Agreement). Press release announces LifeMD financial results for Q3 2026, three months ended September 30, 2026.

What are the latest LFMD SEC filings?

LifeMD, Inc. (LFMD) filed its latest 10-K annual report on March 10, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on August 18, 2026.

What is LFMD's SEC CIK number?

LifeMD, Inc. (LFMD)'s SEC Central Index Key (CIK) is 948320. EDGAR lists every LFMD filing under that number.

Ask anything about LFMD

The research agent reads LFMD's filings, financials, insider trades and 13F holders, then answers with sources.